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Efficacy of Using Cancer Stem Cell Markers in Isolating
and Characterizing Liver Cancer Stem Cells
George S. Wilson,1 Zenan Hu,2 Wei Duan,3 Aiping Tian,1,2 Xin M. Wang,4 Duncan McLeod,5
Vincent Lam,6 Jacob George,1 and Liang Qiao1
Recent evidence suggests that a subset of hepatocellular carcinomas (HCCs) are derived from liver cancer stem
cells (LCSCs). In order to isolate and characterize LCSCs, reliable markers that are specific to these cells are
required. We evaluated the efficacy of a range of cancer stem cell (CSC) markers in isolating and characterizing
LCSCs. We show that the most widely used CSC markers are not specific to LCSCs. By western analysis,
protein expression of the common markers showed no significant difference between HCC tumor tissues and
adjacent non-cancerous liver. Further, isolation of LCSCs from common HCC cell lines using FACScan and
microbeads showed no consistent marker expression pattern. We also show that LCSCs have unique subtypes.
Immunohistochemistry of HCC tissues showed that different HCCs express unique combinations of LCSC
markers. Quantitative real-time polymerase chain reaction analysis showed that LCSCs isolated using dif-
ferent markers in the same HCC phenotype had different expression profiles. Likewise, LCSCs isolated from
different HCC phenotypes with the same marker also had unique expression profiles and displayed varying
resistance profiles to Sorafenib. Thus, using a range of commonly used CSC markers in HCCs and cell lines,
we demonstrate that currently available markers are not specific for LCSCs. LCSCs have unique subtypes that
express distinctive combinations of LCSC markers and altered drug resistance profiles, making their identi-
fication problematic.
Introduction
Hepatocellular carcinoma (HCC) is an aggressivecancer in which the majority of patients will die within a
year of diagnosis [1]. It is currently the fifth most common
cancer worldwide and the thirdmost common cause of cancer
mortality [2]. HCC is more prevalent in Asia and sub-Saharan
Africa, where it accounts for 80% of cases diagnosed world-
wide [2]. The vast majority of these tumors develop as a result
of chronic liver injury caused by infections with hepatitis B
virus (HBV) and hepatitis C virus (HCV), alcohol abuse, non-
alcoholic steatohepatitis, and exposure to liver toxins such as
aflatoxin and oral contraceptives. Among these, HBV and
HCV infections are responsible for more than 80% of all HCC
cases [1–3]. HCC has a bleak prognosis which is largely at-
tributed to a poor understanding of the molecular mecha-
nisms that control the initiation, progression, and treatment
refractoriness of the tumor. Currently available options for the
treatment of advanced liver cancer, including chemotherapy,
internal radiation, local ablation, and anti-angiogenesis ther-
apies, have shown limited efficacy.
It is now recognized that a small proportion of the cells
within HCCs possess stem cell properties, including un-
limited proliferative ability, a strong potential for self-
renewal, and unlimited differentiation ability into cancer
cell progeny [4]. These cells are termed cancer stem cells
(CSCs) or tumor initiating cells. The role of liver cancer stem
cells (LCSCs) in HCC has been verified in immunocom-
promised mice [5]. However, it is currently unknown how
LCSCs originate.
HCC generally develops as a result of chronic liver in-
flammation that is induced most commonly by hepatitis B
and C. In this context, LCSCs are highly active during liver
inflammation and cirrhosis [6], and persistent liver injury
activates the progenitor cell compartment, leading to their
replication [7,8] and an increased ability for clonal expansion
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into tumors [9]. It has been reported that *55% of the small
dysplastic foci that are the premalignant lesions of HCC
consist of progenitor cells [5,6], and about 25%–50% of HCCs
express markers of progenitor cells and possess progenitor
cell compartments [6]. Liver progenitor cells and LCSCs are
types of adult stem cells, which are the only cell type that
persists in the tissue for a sufficient length of time to acquire
genetic changes, leading to neoplastic development, sug-
gesting that HCC is derived from oncogenic mutations in
liver stem cells [10,11]. LCSCs may also be derived from the
dedifferentiation of mature hepatocytes into a dediffer-
entiated state [12].
It is now also believed that CSCs may be responsible for
treatment failure and relapse or metastasis, as these cells are
resistant to most of the currently available chemotherapy
and radiotherapy [10,11]. Therefore, elimination of CSCs has
the potential to improve patient outcomes and survival.
Successful identification of LCSCs is a pre-requisite for a
better understanding of the molecular mechanisms by which
liver cancer initiates, progresses, evades treatment, relapses,
and metastasizes. Currently, identification of CSCs is
achieved through several approaches, including (1) flow
cytometry separation using CSCs surface markers [13]; (2)
detection of side population by the Hoechst 33342 exclusion
assay [14]; (3) in vitro floating tumor sphere formation in
serum-free medium [15] coupled with xenograft tumor for-
mation in immune-deficient mice [16,17]; and (4) other as-
says such as aldehyde dehydrogenase (ALDH) activity assay
[18] and immunohistochemistry analysis [15]. Several LCSC
markers have been reported, including CD133, CD90, CD44,
epithelial cell-adhesion molecule (EpCAM), CD13, OV6, and
ALDH [19,20]. However, the reliability of each of these
markers in identifying true LCSCs varies with LCSCs sorted
from different laboratories showing high heterogeneity [21].
LCSCs isolated using different markers may show similar
stemness. For example, CD90 + cells have been shown to be
present in the majority of HCC but not in cirrhotic patients.
These cells possessed stem cell properties and were able to
stably form tumors in nude mice [20]. Similarly, CD133+
and CD44 + cells displayed stem cell properties and a greater
tumorigenic ability compared with CD133 - and CD44-
cells [19,20]. So far, no universal markers for LCSCs have
been identified, and isolating LCSC on the basis of single
markers is problematic. Further, some stem cell markers may
not be specific to LCSC, and they are generally not univer-
sally expressed in all LCSCs [20,22].
Given the problems of isolating LCSC using stem cell
markers, there is a need for a comprehensive evaluation of
the effectiveness of stem cell markers to characterize and
isolate LCSC. Our study tested a range of LCSC markers in
both human HCC and HCC cell lines to evaluate the effec-
tiveness of these markers to characterize and isolate LCSCs.
Materials and Methods
HCC tissues
Fourteen cases of human HCC and matched adjacent non-
cancerous tissues from patients who had undergone treat-
ment at Westmead Hospital were collected. Tissues were
collected from a single HCC lesion along with surrounding
normal tissue. All HCCs were clinically and pathologically
confirmed. Written consents were obtained from all patients
before sample collection. The study was approved by the
Human Ethics Committee of the Western Sydney Area
Health Service.
Culture of HCC cell lines
The HCC cell line HuH7 was cultured in Dulbecco’s
modified Eagle’s medium + 10% fetal calf serum (FCS) at
37C, 5% CO2. HCC cell lines PLC/PRF/5, SNU182, and
SNU423 were cultured in RPMI + 10% FCS at 37C, 5% CO2.
Antibodies
Unconjugated antibodies against CD44, EpCAM, and al-
pha fetoprotein (AFP) were purchased from Cell Signaling.
Unconjugated antibodies against CD133 and ALDH were
purchased from Abcam. Unconjugated anti-CD90 was pur-
chased from Epitomics. Microbead-conjugated and PE-
conjugated antibodies against CD44, CD133, EpCAM, and
CD90 were purchased from Miltenyi Biotec.
Protein extraction, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis,
and western blots
Tissues were lysed in protein extraction buffer [50mM
Tris-HCL (pH = 7.4), 150mM NaCl, 50mM NaF, 5mM so-
dium pyrophosphate, 1mM ethylenediaminetetraaceticacid,
1mM ethylene glycol tetraacetic acid, 1mM dithiothreitol,
0.1mM phenyl methyl sulfonyl fluoride, 1mM sodium or-
thovanadate, 1% glycerol, 1% Triton X-100, and protease in-
hibitor cocktail] (Roche) using steel beads on a Tissue Lyser
(Qiagen). Cell lysates were centrifuged at 14,000 rpm for
10min at 4C. The protein concentration in the supernatant
was quantified using a DCA Protein Assay (BioRad) with
bovine serum albumin (BSA) as the standard. An equal
amount of protein (30mg) for each sample was loaded onto an
8%–10% sodium dodecyl sulfate (SDS) polyacrylamide gel
and transferred to a polyvinylidene fluoride membrane (Hy-
bond-P; Amersham Biosciences Piscataway). The membranes
were blocked in tris-buffered saline + 0.1% Tween 20 (TBST)
+ 5% skim milk. The membranes were then incubated over-
night in a 1:1,000 dilution of primary antibodies in TBST at
4C. The membranes were washed thrice for 5min in TBST,
incubated in a 1:10,000 dilution of horseradish peroxidise
(HRP)-conjugated anti-rabbit or anti-mouse secondary anti-
bodies in TBST for 1 h, washed again in TBST, and developed
using the Amersham ECL western blotting detection reagents
(GE Healthcare). All membranes were stripped with a strip-
ping buffer (2% SDS, 100mM 2-mercaptoethanol, and
62.5mM Tris-HCl (pH 6.7) at room temperature for 30min
with gentle shaking and re-probed with an antibody against
b-actin (Sigma) as a control for protein loading.
Construction of a tissue microarray
and immunohistochemistry
Formalin-fixed and paraffin-embedded donor HCC
blocks were used to make a single tissue microarray (TMA)
block. In each donor block, morphologically representative
areas were identified and marked on the respective hema-
toxylin and eosin (H&E) slides. Duplicate cores (0.6mm)
were extracted from the chosen region and placed into the
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recipient paraffin block using the Beecher Manual Tissue
Microarrayer Model MTA-1 system (Beecher Instruments).
The differentiation stage, lymphovascular invasion (LVI),
and tumor stage were determined for each HCC tumor
from the H&E slides.
Immunohistochemistry
The TMA blocks constructed earlier were cut into sections
of 4mm thickness, dewaxed in xylene, and rehydrated in
graded alcohols. For antigen retrieval, slides were placed in a
1% (w/v) zinc sulfate antigen retrieval solution and boiled
for 30min in a microwave. Specimens were then allowed to
cool for 15min followed by a 5-min wash in water. Before
immunohistochemical staining, the slides were incubated
with 3% H2O2 in phosphate-buffered saline (PBS) for 10min
to quench endogenous peroxidase activity, washed twice
(5min each) in TBS+ 0.025% Triton X-100, and blocked in
TBS + 1% BSA + 10% FCS for 2 h. For immunohistochemical
staining, consecutive slides were incubated overnight at 4C
with the respective primary antibodies (1:500). The slides
were then washed twice in TBS + 0.025% Triton X-100 and
incubated for 1 h in corresponding HRP-conjugated second-
ary antibody (1:10,000) diluted in TBS + 1% BSA. Slides were
washed in TBST, developed with 2,3-diaminobenzidine tet-
rahydrochloride for 10min, and counterstained with He-
matoxylin QS (Vector Laboratories, Inc.) for 30 s. The slides
were then washed, dehydrated in graded alcohol, mounted
using Safety Mount No. 4 (Fronine Laboratories), and visu-
alized on a Leica DMBL (Leica Microsystems) attached to a
Spot RT KE (Spot Diagnostic Instruments). Images were
analyzed using Spot Basic V4.1 (Spot Diagnostic Instru-
ments). Immunostaining results were quantified using a
TMA staining evaluation protocol. [23].
Magnetic bead separation
A total of 5 · 106 cells were harvested from each of the
HCC cell lines. These cells were then labeled, respectively,
with EpCAM, CD44, CD90, or CD133 antibodies conjugated
to magnetic beads (Miltenyi Biotec) according to the manu-
facturer’s instructions. Cells were then co-labeled with Ep-
CAM, CD44, CD90, or CD133 conjugated to PE (Miltenyi
Biotec) according to the manufacturer’s instructions. Anti-
body positive and negative cells were then separated using
MACS LS separation columns (Miltenyi Biotec) and identi-
fied as antibody-enriched or -depleted cell populations,
respectively.
Flow cytometry
Cells were centrifuged at 1,500 g for 5min. The superna-
tant was discarded, and the cell pellet was resuspended in
PBS, then run on an FACS CantoII Flow Cytometer (Becton
Dickenson). The data were analyzed using BD Diva Software
(Becton Dickenson) to calculate the percentage of positive
cells.
Tumor sphere assay
Cells were resuspended in tumor sphere assay media (1%
w/v sodiumpyruvate, 1%w/vminimumessentialmedia non-
essential amino acids, 1% v/v insulin transferrin selenium,
1mM dexamethasone, 200mM l-ascorbic acid 2-phosphate,
10mM nicotinamide, 20 ng/mL epidermal growth factor, and
10ng/mL fibroblast growth factor-2) at a concentration of
2· 104 cells/mL. One milliliter of the cell suspension was see-
ded on aCostarUltra LowAttachment 6-well plate (Corning).
The number of tumor spheres was counted under a phase-
contrast microscope.
Quantitative real-time polymerase chain
reaction analysis
RNA from EpCAM enriched HuH7 and PLC/PRF/5 cells
were extracted using FavorPrep Tissue Total RNAMini Kit
(Favorgen) according to the manufacturer’s instructions.
cDNA was synthesized from the extracted RNA using M-
MLV Reverse Transcriptase (Promega) according to the
manufacturer’s instructions. Gene expression was quantified
by adding 5 ng of cDNA to 10mL Fast SYBR Green and
0.5 mM forward and reverse primers of the stemness genes
(Oct3/4, TAT, CD90, CYP3A4, HNF3B, AFP, CD13, HNF1A,
CD133, ALDH1A1, CK19, and CD45). Reaction volumes were
adjusted to 20mL with sterile water. Stemness gene expres-
sion was normalized to the expression of the housekeeping
gene b-actin.
Cell proliferation
Cells were seeded at a density of 5 · 103 in a 96-well plate
and cultured overnight. Cells were then treated with vari-
ous concentrations of Sorafenib ranging from 0 to 50 mM
and cultured for a further 24 h. After treatment, cell prolif-
eration was determined by a Cell Proliferation ELISA, BrdU
(Roche Applied Science) according to the manufacturer’s
instructions.
Statistical analysis
Differences between samples were determined using a
two-sample t-test on Microsoft Excel 2010. Differences were
deemed significant if a P-value was less than 0.05.
Results
Expression of LCSC markers in HCC
To investigate the specificity of currently used stem cell
markers in detecting LCSCs, the expression of the three most
commonly used CSC markers (CD44, CD90, and CD133) was
tested by western blots in nine cases of human HCC. As
shown in Fig. 1, there was no significant difference in the
expression of the stem cell markers between tumor tissues
and adjacent non-cancerous liver (P > 0.05, two-way analysis
of variance). The positivity of each of the three CSC markers
varied to a great extent. For example, relative to the sur-
rounding non-cancerous liver and normalized against b-actin
in each compartment, it was evident that increased CD44
expression was found in 3 out of 9 tumors. In another three
tumors, the expression of CD44 was decreased, and in the
remaining cases, no change was found between adjacent
non-cancerous liver and tumor. CD90 was barely detected in
all non-cancerous liver tissues. Increased expression of CD90
was found in 3 out of 9 cases of HCC. For CD133, four HCCs
(4/9) showed increased expression, two (2/9) showed
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decreased expression, and the remaining three showed no
significant changes.
Immunohistochemical staining for CSC markers in human
tumors is a widely used methodology for assessing CSCs in
situ. It can also provide information on the origin, recur-
rence, and metastasis of the cancers, as well as on the pos-
sible correlation between the extent of CSC expression and
patient survival [15]. To determine the accuracy of CSC
markers to identify LCSC, we next examined the expression
patterns of the well-characterized CSC markers CD44, CD90,
CD133 and two other promising markers (EpCAM, and
AFP) in 14 HCC tumor tissues by immunohistochemistry. As
shown in Table 1, of the 14 HCCs tested, only two samples
(HCC 1 and 2) were positive for all five stem cell markers,
five samples (HCC 3–7) were positive for four markers, three
samples (HCC 8–10) were positive for three markers, another
three samples (HCC 11–13) were positive for two, and one
sample (HCC14) was only positive for one marker. Typical
immunostaining results (for HCC 1, 3, 9, and 11 only) are
shown in Fig. 2. We then analyzed the co-expression patterns
for these CSC markers in the 14 HCCs. As shown in Table 2,
none of the CSC markers showed co-expression in all 14
HCCs tested. Co-expression of CD133 with AFP was found
in 12 out of 14 HCC tissues. Co-expression of CD44 with
CD133, CD44 with AFP, and EpCAMwith CD133 was found
in eight HCC cases, respectively. In 7 out of 14 HCC tissues,
AFP co-expressed with EpCAM, and in 6 out of 14 cases,
EpCAM co-expressed with CD44. Only 4 out of 14 HCC
cases showed co-expression of CD133 with CD90 and AFP
with CD90. Three out of 14 cases showed co-expression of
CD44 with CD90, and 2 out of 14 cases showed co-expression
of EpCAM with CD44.
The relationship between HCC marker expression and
disease state was also examined. Table 3 shows that the
FIG. 1. Western blot analysis of cancer stem cell (CSC) markers (CD44, CD90, and CD133) in human hepatocellular
carcinoma (HCC) (A). The house keeping gene b-actin was used as the internal control. (B) Protein expression of the CSC
markers was quantified by densitometry and normalized against the expression of b-actin.
Table 1. Expression of Cancer Stem Cell Markers
in Hepatocellular Carcinoma Tissues
As Determined by Immunohistochemistry
HCC
case CD44 CD90 CD133 EpCAM AFP
No. of positive
markers/total case
1 + + + + + 5/5
2 + + + + + 5/5
3 + + + - + 4/5
4 + - + + + 4/5
5 + - + + + 4/5
6 + - + + + 4/5
7 + - + + + 4/5
8 - + + - + 3/5
9 - - + + + 3/5
10 + - + - + 3/5
11 - - + - + 2/5
12 - - + - + 2/5
13 - - + + - 2/5
14 - - + - - 1/5
HCC, hepatocellular carcinoma; EpCAM, epithelial cell-adhesion
molecule; AFP, alpha-fetoprotein.
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expression of LCSC markers did not relate to LVI (an indi-
cator of metastasis) or tumor stage. However, the expression
of LCSC markers appears to be positively related to the de-
gree of differentiation with a greater percentage of LCSC
markers being positive in tissues with greater differentiation
(Fig. 3; Table 3).
Isolation of LCSCs using stem cell markers
In order to confirm the specificity of the commonly used
CSC markers in isolating LCSCs, four HCC cell lines (HuH7,
SNU423, PLC/PRF/PRF/5, and SNU182) were segregated
into enriched or depleted subpopulations based on the ex-
pression of the CSC markers CD44, CD90, CD133, and Ep-
CAM, and the ability of these marker-enriched fractions to
form spheres in appropriate culture conditions was tested.
By flow cytometry analysis, the proportion of stem cells ex-
pressing the four CSC markers mentioned earlier varied
considerably across the cell lines tested as shown in Table 4.
The vast majority of SNU182 and SNU423 cells were positive
for CD44 (93.4% and 97.8%, respectively), whereas only 3.7%
of HuH7 cells and 0.1% of PLC/PRF/5 cells were positive
for CD44. When the enriched CD44+ cells from HuH7 and
PLC/PRF/5 cell lines were cultured in an appropriate cul-
ture condition, they formed significantly more tumor spheres
than CD44- cells (two sample t-test, P < 0.05) (Table 5;
Fig. 4). The percentage of sphere formation in marker neg-
ative versus positive fractions is shown in Table 5.
CD133 was positive in 43.9% of HuH7 cells, 36.9% of
PLC/PRF/5 cells, and 13.2% of SNU182 cells; whereas no
expression of CD133 was detected in SNU423 cells (Table 4).
The CD133-enriched fraction of SNU182 cells showed sig-
nificantly increased tumor sphere formation compared with
their parental cells (two sample t-test, P < 0.05) (Table 5; Fig.
4). However, the CD133-enriched fraction of HuH7 and
PLC/PRF/5 cells did not exhibit increased tumor sphere
formation (Table 5).
EpCAM was found to be positive in 55.2% of HuH7 cells
and in 61.5% of SNU182 cells, whereas no expression was
detected in SNU423 cells (Table 4). Approximately 0.3% of
PLC/PRF/5 were positive for EpCAM. The EpCAM-
enriched HuH7 and PLC/PRF/5 cells displayed increased
tumor sphere formation compared with their respective pa-
rental cell populations (two sample t-test, P < 0.05) (Table 5;
Fig. 4). The EpCAM-enriched SNU182 cells did not show
increased tumor sphere formation (Table 5).
No CD90 was detected in the four HCC cell lines tested
(Table 4).
FIG. 2. Immunohistochemistry of human HCC. Serial sections from the paraffin-embedded tissue microarray blocks were
used to stain for the CSC markers CD44, CD90, CD133, epithelial cell-adhesion molecule (EpCAM), and alpha-fetoprotein
(AFP). Magnification: · 100. Negative controls for rabbit monoclonal antibodies (CD90 and CD133) and mouse monoclonal
antibodies (CD44, EpCAM, and AFP) are shown for each section.
Table 2. Co-Expression of Cancer Stem Cell
Markers in Hepatocellular Carcinoma Tissues
As Determined by Immunohistochemistry
Markers CD44 CD90 CD133 EpCAM AFP
CD44 — — — — —
CD90 3/14 — — — —
CD133 8/14 4/14 — — —
EpCAM 6/14 2/14 8/14 — —
AFP 8/14 4/14 12/14 7/14 —
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Expression of stemness markers in LCSCs
To determine the validity of using different LCSC markers
to isolate unique LCSC subtypes, a quantitative real-time
polymerase chain reaction array was undertaken to test the
expression of a range of LCSC markers (CD90, CD133, AFP,
CD13, CK19, and ALDH1A1) and the stemness marker (Oct3/
4) in CD44 and EpCAM-enriched fractions of HuH7 cells. As
shown in Fig. 5, in both CD44 and EpCAM-enriched fractions
of HuH7 cells, three stem cell markers CD90, AFP, and CD13
were markedly increased compared with unenriched fractions
(Fig. 5A, B). The stemnesss marker Oct3/4 had a greater in-
crease in expression in EpCAM enriched populations com-
pared with CD44-enriched counterparts. In contrast, in both
CD44 and EpCAM-enriched fractions of PLC/PRF/5 cells,
CD90 and CD13, and to a lesser extent, CD133 was markedly
increased compared with non-enriched cell populations (Fig.
5C, D). AFP did not show a significant change between the
marker-enriched and unenriched fractions. Similar to HuH7
cells, the stemnesss marker Oct3/4 showed increased expres-
sion in EpCAM-enriched but not in CD44-enriched PLC/
PRF/5 cells populations.
Sorafenib resistance of LCSCs
Resistance to chemotherapeutic agents is a clinically rele-
vant feature of CSCs. LCSCs have been shown to be resistant
to Sorafenib [24]. We, therefore, compared the effect of Sor-
afenib on the growth of EpCAM-enriched HCC cells. Ep-
CAM-enriched HuH7 and PLC/PRF/5 cells, as well as their
unenriched counterparts, were treated with various concen-
trations of Sorafenib for 24 h. As expected, at a concentration
of 10 mM and above, EpCAM-enriched HuH7 and PLC/
PRF/5 cells were more resistant to Sorafenib compared with
the unenriched populations (Fig. 6A, B) (two-sample t-test,
P < 0.05). When cell growth was compared between EpCAM-
enriched HuH7 cells and EpCAM-enriched PLC/PRFR/5
cells, EpCAM-enriched PLC/PRF/5 cells were more resis-
tant to Sorafenib treatment than the EpCAM-enriched HuH7
cells (Fig. 6C) (two-sample t-test, P < 0.05).
Discussion
According to current theory, primary liver cancers origi-
nate from either differentiated liver cells (hepatocytes) or
LCSCs [25]. Common causative agents for HCC such as HCV
can induce liver cancer via activation of CSC pathways [25].
Further, currently available HCC therapies often fail because
of their limited ability to kill CSCs. These CSCs generally
remain quiescent but viable and retain the capability of re-
generating new tumors [26]. Given the importance of CSCs
in HCC, therefore, characterization of CSCs from the tumor
bulk is an important pre-requisite for effective CSC targeting.
Many CSC markers have been used to isolate and charac-
terize LCSCs. The most commonly used markers include
CD133, CD44, CD90, CK19, Epcam, and ALDH [5,11]. In our
study, we observed that these CSC markers were present in
both tumors and adjacent non-cancerous liver, and that the
positive percent and staining intensity vary considerably be-
tween cases. No consistent expression patterns were observed
in the available cases. Furthermore, LCSCs isolated using
different markers in the same cell line or the same markers in
different cell lines had a unique expression profile. We believe
that this finding reflects the strong heterogeneity of origin of
liver cancer and possibly the varied etiology of HCC. Our
findings that the studied CSC markers were expressed at
various levels in different HCC cell lines further supports the
heterogeneous nature of liver cancer cells.
Studies by others have also shown that CSC markers are
not specific to LCSCs. In particular, CD133 was found to be
expressed in both LCSCs and hepatocytes [22]. CD133 is the
most abundant CSC marker for many solid tumors and he-
matopoetic malignancies. Its role as a marker in liver cancer is
questionable, as the percentage of tumor cells expressing
CD133 varied considerably across the commonly used HCC
cell lines, ranging from < 1% in SMMC-7721 cells, to 66% in
Table 3. Expression of Liver Cancer Stem Cell
Markers and Their Correlation with Degree
of Hepatocellular Carcinoma Tumor Differentiation,
Lymphovascular Invasion, and Staging
HCC
case
Ratio of
positive markers
Differentiation
status LVI
Tumor
stage
1 5/5 Moderate No T1
2 5/5 Moderate No T1
3 4/5 Well No T2
4 4/5 Moderate No T2
5 4/5 Moderate Yes T2
6 4/5 Moderate No T1
7 4/5 Moderate to poor Yes T2
8 3/5 Moderate to poor Yes T3b
9 3/5 Moderate to poor Yes T4
10 3/5 Moderate No T1
11 2/5 Moderate Yes T2
12 2/5 Moderate to poor Yes T1
13 2/5 Moderate Yes T2
14 1/5 Poor No T1
Tumor staging: T1, solitary tumor without vascular invasion; T2,
solitary tumor with vascular invasion or multiple tumors, none more
than 5 cm; T3a, multiple tumors more than 5 cm; T3b, single tumor or
multiple tumors of any size involving a major branch point of the
portal vein or hepatic vein; T4, tumor (s) with direct invasion of
adjacent organs other than the gallbladder or with perforation of
visceral peritoneum.
LVI, lymphovascular invasion.
FIG. 3. Percentage of liver cancer stem cell (LCSC) markers
positive in HCCs with different differentiation status.
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HuH7 cells, and > 90% in Hep3B cells [22]. In human liver, it
was reported that CD133 is sporadically expressed in 1%–3%
of HCC tissues and 0.025%–0.1% of non-tumorous liver [27].
CD133 has also been observed in ductular reactions in both
acute and chronically damaged livers [28] as well as in normal
biliary epithelium [29]. In our study, 43.9% of non-enriched
HuH7 cells and 36.9% of non-enriched PLC/PRF/5 cells were
positive for CD133. By immunoblotting and immunohisto-
chemistry, all HCC tissues that we studied expressed CD133.
However, when the well-established CSC markers CD44 and
EpCAM were used to enrich the LCSC cell population, it was
revealed that the expression of CD133 between the marker
enriched and non-enriched population was minimal, and the
expression level of CD133 was much less than that of the other
markers such as CD90 and CD13. In addition, CD133 co-ex-
pressed with four other markers (CD44, CD90, EpCAM, and
AFP) in only 2 out of 14 HCC cases. Clearly, caution should be
exercised in using CD133 as an LCSC marker.
CD44, a cell adhesion molecule, is another well-character-
ized LCSC marker [30,31]. Aberrant expression of CD44 has
been linked to the development of several human tumors such
as prostate, colorectal, and breast cancer [31–33], and as a CSC
marker for these tumors [34–36]. As previously reported, the
tumorigenic properties of some CSCs isolated using other
markers such as CD133 or CD90 were attributed to the ex-
pression of CD44 [20,22]. The expression of CD44 in HCC is
also related to a higher frequency of extrahepatic metastasis
and poor survival [37]. It has, thus, been suggested that the
combination of CD44 with other markers such as CD90+/
CD44+ and CD44+/CD133+ may be of more value in
isolating LCSCs [21,22]. Our data shows high expression of
CD44 in most HCC (8/14), and CD44 appears to co-express
with many of the other CSC markers studied. The CD44+
fraction of HuH7 and PLC/PRF/5 showed increased numbers
of tumor spheres compared with the CD44- fractions, and the
CD44-enriched fractions of HuH7 and PLC/PRF/5 cells
showed increased resistance to Sorafenib. However, the other
two cell lines tested (SNU423 and SNU182) did not show in-
creased tumor sphere formation in the CD44+ -enriched frac-
tion. These data demonstrate that CD44 may be a reliable
LCSC marker for some but not all types of HCC cells, again
reflecting the well-reported heterogeneity of liver cancer.
CD90 expression was shown in a previous study to be ex-
pressed in all HCCs andHCC cell lines, but with no expression
in cirrhotic or adjacent noncancerous tissue [20,38]. In our
study, CD90 was detectable only in a minority of HCC tissues,
and noCD90was detected in the four cell lineswe tested. Thus,
the efficacy of using CD90 as an LCSC marker is unclear.
Based on published data and our own studies, caution
needs to be taken in isolating and characterizing LCSC using
the currently available CSC markers. Combining more than
one marker has been shown to increase the isolating effi-
ciency [21,22]. However, in immunohistochemistry analysis,
we could not reveal a ubiquitous co-expression pattern be-
tween any of the LCSC markers. CD90 and CD44 only co-
expressed in a fraction of HCC tissues tested. The best co-
expression pattern was between CD133 and AFP. However,
AFP is a well-characterized marker that is used to detect all
HCCs [39], and CD133 expression appears to be non-specific
with no significant difference in expression between human
HCC tumor tissues and adjacent noncancerous tissues. Fur-
thermore, AFP appears to be markedly up-regulated in Ep-
CAM-enriched HuH7 cells, but not in PLC/PRF/5 cells,
suggesting a possible cell-specific phenotype.
Our findings suggest that LCSCs have unique subtypes.
Using different markers to isolate LCSCs in the same HCC
cell lines, or isolating LCSCs from different cell lines using
the same markers may result in different phenotypes, each
with a distinct expression profile of the LCSC markers and
stemness markers. LCSCs isolated using the same markers
from different cell lines may also have unique biological
Table 4. Expression Percentage of Common
Cancer Stem Cell Markers in Hepatocellular
Carcinoma Cell Lines by Flow Cytometry
Cell type CD44 (%) CD90 (%) CD133 (%) EpCAM (%)
HuH7 3.7 0 43.9 55.2
SNU423 93.4 0 0 0
PLC/PRF/5 0.1 0 36.9 0.3
SNU182 97.8 0 13.2 61.5
Table 5. Percentage of Cells that Formed Tumor Spheres in the Antibody-Enriched ( + Fraction)
Relative to Antibody-Depleted Fractions ( - Fraction) from Hepatocellular Carcinoma Cells,
As Determined by Tumor Sphere Assay
CSC markers
Cell type
CD44 CD90 CD133 EpCAM
+ Fraction - Fraction +Fraction - Fraction +Fraction -Fraction +Fraction - Fraction
HuH7 0.7860.06 0.30 – 0.06 No expression 0.69 – 0.07 0.71 – 0.80 1.00 – 0.07 0.25 – 0.05
SNU423 High expression No expression No expression No expression
PLC/PRF/5 0.4560.03 0.00 – 0.00 No expression 0.51 – 0.11 0.61 – 0.12 2.1660.25 0.00 – 0.00
SNU182 High expression No expression 3.0260.19 1.39 – 0.05 3.20 – 0.35 3.08 – 0.26
No expression: No expression of CSC marker by flow cytometry.
High expression:> 90% of cells were positive for CSC marker by flow cytometry.
Antibody-enriched fraction (+ fraction) formed higher percentage of tumor spheres compared with antibody-depleted fraction ( - fraction)
(shown in bold, two sample t-test, P< 0.05). The percentage of tumor spheres was determined as follows: [no. of spheres formed/total
number of cells seeded]· 100.
Data are expressed as mean– standard deviation (n = 3).
CSC, cancer stem cell.
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FIG. 4. Number of tumor spheres (A) and overall percentage of tumor spheres (B) in antibody-enriched and antibody-
depleted fractions of HCC cell lines (HuH7, PLC/PRF/5, and SNU182 cells). *Indicates significantly greater number of
tumour spheres in antibody enriched compared to antibody depleted fractions. Significant differences were determined by a
two sample t-test (p< 0.05).
FIG. 5. Expression of CSC markers (CD90, CD133, AFP, CD13, CK19, and ALDH1A1) and the stemness marker (Oct/3/4)
in CD44 (A, C) and PLC/PRF/5 (B, D)-enriched HuH7 cells (A, B) and PLC/PRF/5 cells (C, D). Expression was detected by
quantitative real-time polymerase chain reaction, and normalized against the expression of b-actin.
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properties with different resistant levels to Sorafenib. Similar
phenomena have been reported in breast cancer [40,41].
Therefore, a combination of at least two markers may pro-
vide a better efficiency in LCSC isolation and characteriza-
tion, as was reported by others [22].
In summary, our current study has further confirmed the
heterogeneity and complex nature of CSC biology. By using a
range of commonly used LCSC markers on the same HCCs
and cell lines, our study is the first to provide a comprehen-
sive screen of LCSC markers in HCC. We have shown that the
reported markers are not specific to LCSCs, and LCSC sub-
types express different LCSC markers. A ‘‘universal’’ LCSC
marker(s) is (are) unlikely present. We believe that in order to
utilize LCSC markers to isolate LCSC, a wide range of
markers should be examined for each HCC phenotype and
linked with experimental evidence in immunodeficient mice
(such as NOD-SCID mice) to confirm LCSC enrichment.
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